ClinicalTrials.gg
RecruitingNCT06965049PROB-PROMUpdated Nov 18, 2026

Vaginal Probiotics During Pregnancy After Premature (24-32 Weeks of Gestation) Preterm Rupture of Membranes

An interventional study of Probiotic and Placebo in Pregnancy, Prematurity and PPROM, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Now RecruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 139 studies in Premature Birth with a site in Canada — 26 open to participants now, 34 under way, 2 of them phase 3. Premature Birth · Canada.

Planned enrollment
53rd of 106
80 · median 80
Started
2026
with 6 others
No phase
65 of 139
9 open now
Primary completion
2027-12
later than 23 of 33 live
Registered
129th of 139
by date

Among the 139 studies in Premature Birth with a site in Canada, this one is the 53rd largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2026, is one of 65 with no phase, reaches primary completion later than 23 of the 33 other live ones, and was the 129th registered.

Premature Birth

2,556 studies on the registry are indexed under Premature Birth; 503 are open to participants now.

Browse Premature Birth studies →

Open to participants now

26 of the 139 studies in Premature Birth with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 317 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 225 (71%) stop at 75 or younger; 242 take children under 18; 104 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Premature Birth with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the feasibility of the randomized controlled trial (RCT).

Secondary objectives include comparing the microbiota of preterm babies born after premature rupture of membranes across study groups.

To achieve this, participants will be asked to:

  • Use the vaginal study product from the time of membrane rupture until delivery
  • Keep a diary documenting their symptoms and treatment adherence
  • Provide vaginal secretion samples and stool samples from their baby
Read the detailed description

Premature rupture of fetal membranes before labor (PPROM) accounts for 30% of preterm births. Since PPROM is strongly associated with ascending vaginal infection, antibiotics are recommended during the latent period (LP) (the interval between rupture and birth). While they prolong the LP and improve neonatal health, they also exacerbate pre-existing vaginal dysbiosis. The addition of vaginal probiotics (VP) helps stabilize the vaginal microbiota (VM) and increase Lactobacillus levels. By enhancing the presence of beneficial bacteria in the vagina, probiotics help restore the balance between beneficial and pathogenic microbes, potentially reducing uterine infection and improving the fetal intestinal microbiota.

Pathophysiological Hypotheses for Improving Neonatal Health

The use of VP may influence neonatal outcomes through three potential mechanisms:

i) Reduction of vaginal dysbiosis: Prolongs pregnancy and mitigates complications related to fetal immaturity (e.g., decreases risk of intraventricular hemorrhage).

ii) Reduction of intrauterine infection/inflammation: Lowers neonatal complications associated with inflammation (e.g., reduces incidence of cystic periventricular leukomalacia).

iii) Improvement of neonatal intestinal microbiota (NIM) through probiotic ingestion: Decreases complications linked to neonatal dysbiosis (e.g., reduces risk of necrotizing enterocolitis [NEC]).

Primary Objectives

  • To assess the validity of:

    i) A recruitment rate > 35% ii) A treatment adherence rate > 80% iii) A sample attrition rate \< 5%

  • To identify barriers and facilitators in different settings for the implementation of the randomized controlled trial (RCT).

Secondary Objectives

  • To compare the presence of probiotics in the vaginal microbiota and neonatal stool (meconium and at 7 days of life).
  • To measure the effect of probiotics on the evolution of maternal vaginal microbiota and neonatal intestinal microbiota.

Population Pregnant women aged 18 years or older giving birth at one of the eight centers participating in the study in Quebec and Ontario, Canada. Participants will be randomly assigned, in a blinded manner, to either the probiotic or placebo group.

03

Conditions studied

  • Pregnancy
  • Prematurity
  • PPROM

Keywords

  • pregnancy
  • prematurity
  • PPROM
  • vaginal probiotics
  • microbiota
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women ≥ 18 years of age;
  • mono-fetal pregnancy;
  • treated for PPROM between 24 and 32 weeks of gestation with latency period between 12 hours and \< 7 days in one of the study centers with expectant management;
  • speaking and able to read French or English.

Exclusion criteria

Exclusion Criteria:

  • Presence of active labor;
  • Situation contraindicating expectant management (e.g., infection);
  • Significant malformation, chromosomal anomaly, or fetal death;
  • Signs of fetal distress;
  • Allergy or intolerance to any of the following substances: vitamin C (ascorbic acid), magnesium stearate, maltodextrin, gelatin, yeast, sucrose, trehalose;
  • Allergy to soy or lactose;
  • Weakened immune system (e.g., AIDS, prolonged treatment, etc.);
  • Vaginal probiotics intake 15 days before study inclusion;
  • Oral probiotic intake 30 days before study inclusion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Probiotics group

    Probiotics is a mix of probiotic strains.

    Other: Probiotic

  • Placebo comparator
    Placebo group

    Capsule of sugar, same appearance than the probiotic.

    Other: Placebo

Interventions

  • OtherProbiotic

    Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery

  • OtherPlacebo

    Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    To assess the feasibility of the study, each local site team will complete a dashboard documenting every individual met and informed about the study. This dashboard will be used to calculate the recruitment rate, using the formula: Recruitment rate = (Number of eligible patients - Number of patients who did not consent) / Number of eligible patients Additionally, the dashboard will track reasons for acceptance or refusal.

    Time frame: 7 months

  2. Feasability dashboard

    The attrition rate will be explored to assess feasability of the study. Attrititon rate = (# participants who dropped out / total of participants).

    Time frame: 7 months

  3. Treatment adherence

    Finally, number of caps took during the treatment phase will be reported to explore the adherence of treatment.

    Time frame: 7 months

Secondary outcomes

  1. Probiotics primers

    Evaluate the presence or absence of probiotics in the various samples, i.e. vaginal secretions, meconium and 7-day-old baby's stool, using specific primers to detect strains.

    Time frame: From enrollement to infant 7th day of life

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Protocol, Statistical Analysis Plan (SAP) and informed Consent Form (ICF). No data concerning individual participant will be shared or published.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The supporting information will be shared before the end of the study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Sep 2025 → Dec 2026, primary completion Mar 2026 → Dec 2027 and completion May 2026 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
May 11, 2025
StartEst.
Dec 1, 2026was Sep 2025
Primary completionEst.
Dec 31, 2027was Mar 2026
CompletionEst.
Sep 29, 2028was May 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added, 1 site removed
Show site
  • Centre hospitalier universitaire Sainte-Justine · Montreal, Canada
Show 1 removed
  • Centre de recherche du CHUM · Montreal, Canada
Nov 18, 2026
Start date
Sep 1, 2025→Dec 1, 2026
Nov 18, 2026
Primary completion
Mar 1, 2026→Dec 31, 2027
Nov 18, 2026
Study completion
May 2026→Sep 29, 2028
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Centre hospitalier universitaire Sainte-Justine · Montreal, Canada
    Show 1 removed
    • Centre de recherche du CHUM · Montreal, Canada
    Start date Sep 1, 2025→Dec 1, 2026
    Primary completion Mar 1, 2026→Dec 31, 2027
    Study completion May 2026→Sep 29, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06965049
Collaborators
Lallemand Health Solutions, Canada
Responsible party
Sponsor
First posted
May 11, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Sep 29, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Jean-Charles Pasquier
Contact
jean-charles.pasquier@umontreal.ca
819-679-2212
Sarah Bilodeau
Contact
sarah.bilodeau.chum@ssss.gouv.qc.ca
514-890-8000 ext. 30620

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion